ABL successfully validated and implemented a receptor occupancy assay on behalf of a Phase II clinical trial. The pharmacodynamic profile of this monoclonal antibody, established from our high-quality data, when combined with additional PK and efficacy data, proved instrumental in informing decisions on dose selection for the following clinical trials.
For General Inquiries and Catalog Product Orders
9800 Medical Center Drive, Building D
Rockville, MD 20850 USA
Toll Free: 800-225-5600
Phone: 301-881-5600
Email: info@ablinc.com
